BDBM408717 N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 41::US10730874, Example 00397::US11001578, Example 41::US11084809, Example 41::US11198691, Example 41::US11352356, Table II.3::US11584735, Example 41 of WO2016/083820

SMILES COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nccc(OC)c1F

InChI Key InChIKey=KGMPDQIYDKKXRD-UHFFFAOYSA-N

Data  1 KI  41 IC50  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 408717   

TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataKi:  3nMAssay Description:Reversible inhibition of human plasma kallikrein assessed as inhibition constantMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataIC50:  3.30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataIC50:  3.30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataIC50:  3.30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataIC50:  3.30nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods. Human KLK1 (Callbiochem) was incubated at 25° C. with the fluoroge...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataIC50:  6nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataIC50:  54nMAssay Description:Inhibition of DXS induced human whole plasma kallikrein using H-D-Pro-Phe-Arg-AFC as substrate preincubated for 5 mins followed by DXS stimulation by...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataIC50:  3.30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717( N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(met...)
Affinity DataIC50:  3.30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...More data for this Ligand-Target Pair
In DepthDetails US Patent